Dr. Stephen Moses is a physician and scientist who has made major contributions globally to understanding biological and behavioral risk factors for sexually transmitted infections (STIs), particularly HIV infection, and translating research findings into practice. He is currently a Professor in the Departments of Community Health Sciences and Medical Microbiology and Medicine at the University of Manitoba.
Dr. Nelly Mugo is a reproductive health specialist and has led qualitative and quantitative studies of ART for HIV prevention, cervical intraepithelial lesions, PrEP, fertility intention, and contraceptives in collaboration with scientists from Kenya, Uganda, and the USA. She is currently a Senior Principal Clinical Research Scientist at the Kenya Medical Research Institute (KEMRI) and Associate Professor at the University of Washington.
Dr. Marrianne Mureithi is a microbiologist by training and has been involved in research related to HIV cure and remission. She is part of a dynamic international scientific team in the Vaccine Immunology Science and Technology for Africa (VISTA) programme which is under IAVI. She is involved in designing and assessing the next generation of AIDS vaccine immune – candidates and making a unique contribution to the broader field of HIV vaccine and cure research. She is the Ag. Chair, Department of Medical Microbiology, School of Medicine, College of Health Sciences, University of Nairobi.
Dr Julius Oyugi has focused on investigating uncommon immunity among patients exposed to MTB and surveillance of haemorrhagic fever. He has a PhD in virology and immunology and is currently the Deputy Director, Institute of Tropical and Infectious Diseases, University of Nairobi, Assistant Professor, Department of Medical Microbiology, University of Manitoba and Lecturer, Department of Medical Microbiology, University of Nairobi.
Dr. James Blanchard is an epidemiologist and public health specialist focusing on global health specifically how the characteristics of individuals, communities, and large populations contribute to the local and global distribution of communicable and non-communicable diseases. He is currently the director of the Institute of Global Public Health at the University of Manitoba. He has also provided leadership to the design and implementation of large public health programs related to HIV/AIDS and maternal, neonatal, and child health in India, other Asian and African countries.
Dr. Keith Fowke’s work has focused on studying HIV persistence and developing strategies towards a functional HIV cure. He has a particular interest in training young investigators and has led training programs in global health across multiple countries. He is currently the head of the Department of Medical Microbiology & Infectious Diseases and professor in the Department of Community Health Sciences, University of Manitoba.
Mr Peter Mwaura has 17 years of senior leadership experience working both in the private sector and non-profit sector. He has worked as Associate Director at Evidence Action, Head of Operations at Technoserve Tanzania, and held senior management positions at Africa Now (Now Self Help Africa) and Innovations for Poverty Action. He has experience in the management of grants, finance, and operations. He has an MBA in Strategic Management from the United States International University-Africa (USIU-A) and a postgraduate diploma in Human Resources Management and a CPA 1. He is the Chief Executive Officer of Partners for Health and Development in Africa and an ex-officio member of the board.
The study aims to assess the HIV prevention outcomes in programmes with female sex workers (FSW) and men who have sex with men (MSM) in Nairobi, Kenya. The study will use polling booth method, a novel data collection tool used to collect behavioral data. It is a group interview method in which individuals provide responses through a ballot box in an unlinked and anonymous way. The sample size for the quantitative survey is 680 FSW and 379 MSM. Sampling procedure will use a two-stage i) random selection of participants ii) HIV rapid tests will be conducted for all consenting participants; urine rapid tests will be conducted for all those who report to be on PrEP to test for tenofovir and blood samples will be collected from all those who are positive to test for HIV recency and viral suppression.
The study was initiated in March 2023.
The study population includes two key population groups: female sex workers and men who have sex with men and will take place in 4 groups where a sample size of each group will be divided by an average of 10-12 respondents per Polling Booth Surveys (PBS) to arrive at the number of PBS to be conducted. The study will be using the list of locations and the population size estimation of mapping conducted in the year 2018 and a will take place in 17 sub-counties in Nairobi county.